Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL -- Ignore unavailable to you. Want to Upgrade?

To: arnold silver who wrote (1399)	7/19/1998 12:48:00 PM
From: WWS	Read Replies (1) \| Respond to of 1704

Arnold, it is clear to me that VMRX risks delisting if the bid price is less than $1/share for 30 consecutive days. While it has flirted with the $1 mark, it has not yet fallen below this level for 30 straight days. But if and when it does, the delisting "countdown" will be triggered, regardless of the company's possessing sufficient "net tangible assets" (the old "escape hatch" clause which is now closed). This is exactly what happened to another small biotech, Techniclone (TCLN), which I also had the misfortune to own recently. Fortunately for them good news intervened during the countdown period and pulled their share price back above $1/share. Any day now if I were VMRX I'd expect to receive a notice that Innovir is threatened with the loss of its NASDAQ small cap listing by virtue of having a stock price below the $1 minimum. And, if I were still a VMRX shareholder I'd certainly be alert for the possibility of a reverse split to avert the chance of VMRX's own delisting. Best Regards, Bill.